Teza Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $306K | Sell |
2,434
-2,870
| -54% | -$361K | 0.23% | 179 |
|
|
2025
Q1 | $587K | Sell |
5,304
-12,560
| -70% | -$1.39M | 0.27% | 118 |
|
|
2024
Q4 | $2.44M | Buy |
17,864
+765
| +4% | +$104K | 0.37% | 67 |
|
|
2024
Q3 | $1.97M | Buy |
17,099
+7,055
| +70% | +$813K | 0.22% | 137 |
|
|
2024
Q2 | $1.38M | Buy |
10,044
+5,359
| +114% | +$738K | 0.17% | 190 |
|
|
2024
Q1 | $646K | Sell |
4,685
-937
| -17% | -$129K | 0.09% | 295 |
|
|
2023
Q4 | $741K | Sell |
5,622
-3,117
| -36% | -$411K | 0.12% | 229 |
|
|
2023
Q3 | $983K | Buy |
+8,739
| New | +$983K | 0.16% | 187 |
|
|
2023
Q1 | – | Sell |
-15,691
| Closed | -$1.87M | – | 642 |
|
|
2022
Q4 | $1.87M | Buy |
15,691
+11,039
| +237% | +$1.32M | 0.36% | 66 |
|
|
2022
Q3 | $494K | Buy |
+4,652
| New | +$494K | 0.1% | 285 |
|
|
2020
Q3 | – | Sell |
-6,527
| Closed | -$796K | – | 531 |
|
|
2020
Q2 | $796K | Buy |
6,527
+2,746
| +73% | +$335K | 0.18% | 175 |
|
|
2020
Q1 | $327K | Buy |
3,781
+802
| +27% | +$69.4K | 1.04% | 33 |
|
|
2019
Q4 | $320K | Buy |
+2,979
| New | +$320K | 0.09% | 403 |
|
|
2017
Q2 | – | Sell |
-6,795
| Closed | -$294K | – | 241 |
|
|
2017
Q1 | $294K | Buy |
+6,795
| New | +$294K | 0.09% | 352 |
|